Skip to main content

Advertisement

Figure 5 | Cell & Bioscience

Figure 5

From: Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen

Figure 5

Characterization of the role of CD8+ T cells in tumor protection elicited by the pcDNA3-MCC/ST vaccine. Vaccinated mice were boosted two times at the same dose and regimen at one week intervals. Beginning 1 day after last vaccination, vaccinated mice were intraperitoneally injected with anti-CD8 monoclonal antibody other day. Antibody-depleted mice were then challenged with B16/ST tumor (1×105 cells/mouse) subcutaneously in the right flank on day 22 after vaccination. Mice were monitored for evidence of tumor growth by inspection, palpation and tumor size was measured once a week. (A) Survival analysis of B16/ST tumor-bearing mice treated with pcDNA3-MCC/ST DNA vaccine. (B) Tumor size analysis of B16/ST tumor-bearing mice treated with pcDNA3-MCC/ST DNA vaccine.

Back to article page